AXGN to buy BioCircuit for $200 million cash acquisition
AXGN will pay $200 million in cash to acquire BioCircuit, adding NerveTape and an FDA-approved suture-less nerve repair device to its portfolio. The deal is expected to be accretive to revenue and EBITDA by 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.